$27.37
Live
Insights on Omnicell Inc
Revenue is down for the last 3 quarters, 298.97M → 258.84M (in $), with an average decrease of 6.7% per quarter
Netprofit is down for the last 2 quarters, 5.55M → -14.37M (in $), with an average decrease of 358.9% per quarter
In the last 1 year, Healthequity Inc has given 41.9% return, outperforming this stock by 96.3%
In the last 3 years, Healthequity Inc has given 8.6% return, outperforming this stock by 88.2%
1.1%
Downside
Day's Volatility :4.4%
Upside
3.34%
6.14%
Downside
52 Weeks Volatility :66.7%
Upside
64.52%
Period | Omnicell Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -16.85% | 1.9% | 0.0% |
6 Months | -23.62% | 10.7% | 0.0% |
1 Year | -54.42% | 4.6% | -1.1% |
3 Years | -79.69% | 14.2% | -22.1% |
Market Capitalization | 1.3B |
Book Value | $26.11 |
Earnings Per Share (EPS) | -0.45 |
PEG Ratio | 2.28 |
Wall Street Target Price | 34.5 |
Profit Margin | -1.78% |
Operating Margin TTM | -9.0% |
Return On Assets TTM | -0.61% |
Return On Equity TTM | -1.76% |
Revenue TTM | 1.1B |
Revenue Per Share TTM | 25.37 |
Quarterly Revenue Growth YOY | -13.0% |
Gross Profit TTM | 596.7M |
EBITDA | 37.1M |
Diluted Eps TTM | -0.45 |
Quarterly Earnings Growth YOY | -0.68 |
EPS Estimate Current Year | 1.07 |
EPS Estimate Next Year | 1.43 |
EPS Estimate Current Quarter | 0.15 |
EPS Estimate Next Quarter | 0.31 |
What analysts predicted
Upside of 26.05%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 787.3M | ↑ 9.93% |
Net Income | 37.7M | ↑ 83.11% |
Net Profit Margin | 4.79% | ↑ 1.91% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 897.0M | ↑ 13.94% |
Net Income | 61.3M | ↑ 62.58% |
Net Profit Margin | 6.84% | ↑ 2.05% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 892.2M | ↓ 0.54% |
Net Income | 32.2M | ↓ 47.51% |
Net Profit Margin | 3.61% | ↓ 3.23% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 1.1B | ↑ 26.88% |
Net Income | 77.8M | ↑ 141.81% |
Net Profit Margin | 6.88% | ↑ 3.27% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 1.3B | ↑ 14.48% |
Net Income | 5.6M | ↓ 92.74% |
Net Profit Margin | 0.44% | ↓ 6.44% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 1.1B | ↓ 11.48% |
Net Income | -20.4M | ↓ 460.68% |
Net Profit Margin | -1.78% | ↓ 2.22% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 348.1M | ↑ 5.03% |
Net Income | 16.8M | ↑ 84.96% |
Net Profit Margin | 4.82% | ↑ 2.08% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 297.7M | ↓ 14.48% |
Net Income | -28.4M | ↓ 269.36% |
Net Profit Margin | -9.54% | ↓ 14.36% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 290.6M | ↓ 2.37% |
Net Income | -15.0M | ↓ 47.2% |
Net Profit Margin | -5.16% | ↑ 4.38% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 299.0M | ↑ 2.87% |
Net Income | 3.5M | ↓ 123.01% |
Net Profit Margin | 1.15% | ↑ 6.31% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 298.7M | ↓ 0.1% |
Net Income | 5.6M | ↑ 60.91% |
Net Profit Margin | 1.86% | ↑ 0.71% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 258.8M | ↓ 13.33% |
Net Income | -14.4M | ↓ 358.87% |
Net Profit Margin | -5.55% | ↓ 7.41% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.1B | ↑ 10.3% |
Total Liabilities | 401.6M | ↓ 13.28% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.2B | ↑ 14.76% |
Total Liabilities | 395.6M | ↓ 1.51% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.8B | ↑ 47.04% |
Total Liabilities | 857.0M | ↑ 116.66% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 2.1B | ↑ 17.43% |
Total Liabilities | 995.8M | ↑ 16.2% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 2.2B | ↑ 3.19% |
Total Liabilities | 1.1B | ↑ 8.52% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 2.2B | ↑ 0.73% |
Total Liabilities | 1.0B | ↓ 3.95% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.2B | ↑ 2.26% |
Total Liabilities | 1.0B | ↑ 0.53% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.2B | ↑ 1.43% |
Total Liabilities | 1.1B | ↑ 3.48% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.3B | ↑ 1.81% |
Total Liabilities | 1.1B | ↑ 2.56% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.2B | ↓ 2.53% |
Total Liabilities | 1.0B | ↓ 7.04% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.2B | ↑ 1.26% |
Total Liabilities | 1.0B | ↑ 0.37% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.2B | ↑ 0.24% |
Total Liabilities | 1.0B | ↑ 0.37% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 104.0M | ↑ 318.64% |
Investing Cash Flow | -54.4M | ↑ 55.41% |
Financing Cash Flow | -13.6M | ↑ 37.66% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 145.0M | ↑ 39.48% |
Investing Cash Flow | -61.7M | ↑ 13.41% |
Financing Cash Flow | -23.5M | ↑ 72.68% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 185.9M | ↑ 28.18% |
Investing Cash Flow | -279.9M | ↑ 353.86% |
Financing Cash Flow | 456.3M | ↓ 2043.31% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 231.8M | ↑ 24.72% |
Investing Cash Flow | -412.5M | ↑ 47.39% |
Financing Cash Flow | 47.4M | ↓ 89.62% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 77.8M | ↓ 66.45% |
Investing Cash Flow | -58.7M | ↓ 85.78% |
Financing Cash Flow | -21.0M | ↓ 144.24% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 21.2M | ↓ 321.7% |
Investing Cash Flow | -15.9M | ↑ 132.76% |
Financing Cash Flow | 9.1M | ↓ 723.69% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 82.2M | ↑ 287.97% |
Investing Cash Flow | -17.3M | ↑ 8.73% |
Financing Cash Flow | 3.6M | ↓ 60.67% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 12.8M | ↓ 84.46% |
Investing Cash Flow | -13.6M | ↓ 20.94% |
Financing Cash Flow | 3.9M | ↑ 8.42% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 72.9M | ↑ 470.89% |
Investing Cash Flow | -14.8M | ↑ 8.63% |
Financing Cash Flow | 3.6M | ↓ 6.71% |
Sell
Neutral
Buy
Omnicell Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Omnicell Inc | 0.11% | -23.62% | -54.42% | -79.69% | -63.29% |
Solventum Corp | -8.1% | -8.1% | -8.1% | -8.1% | -8.1% |
Veeva Systems Inc. | -12.34% | 1.98% | 7.91% | -29.07% | 47.16% |
Ge Healthcare Technologies Inc. | -2.31% | 33.35% | -1.77% | 42.57% | 42.57% |
Healthequity Inc | 0.62% | 11.22% | 41.89% | 4.64% | 13.16% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Omnicell Inc | 470.14 | NA | 2.28 | 1.07 | -0.02 | -0.01 | NA | 26.11 |
Solventum Corp | NA | NA | NA | 0.0 | 0.12 | 0.08 | NA | NA |
Veeva Systems Inc. | 61.82 | 61.82 | 1.35 | 4.76 | 0.13 | 0.05 | NA | 28.8 |
Ge Healthcare Technologies Inc. | 28.4 | 28.4 | 20.11 | 4.3 | 0.19 | 0.06 | 0.0 | 15.67 |
Healthequity Inc | 126.86 | 126.86 | 2.29 | 2.19 | 0.03 | 0.03 | NA | 23.63 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Omnicell Inc | Buy | $1.3B | -63.29% | 470.14 | -1.78% |
Solventum Corp | NA | $11.7B | -8.1% | NA | 16.42% |
Veeva Systems Inc. | Buy | $32.1B | 47.16% | 61.82 | 22.24% |
Ge Healthcare Technologies Inc. | Buy | $39.4B | 42.57% | 28.4 | 8.02% |
Healthequity Inc | Buy | $7.0B | 13.16% | 126.86 | 5.57% |
BlackRock Inc
Vanguard Group Inc
State Street Corporation
Champlain Investment Partners, LLC
ClearBridge Advisors, LLC
Morgan Stanley - Brokerage Accounts
since 1992, omnicell has been creating new efficiencies to improve patient care, anywhere it is delivered. omnicell is a leading supplier of comprehensive automation and business analytics software for patient-centric medication and supply management across the entire health care continuum—from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. omnicell’s automated hardware/software systems for medication dispensing include solutions from the point of entry into the hospital through the central pharmacy, nursing unit, operating room, and patient bedside. our supply management systems promote greater cost control and charge capture for payer reimbursement, and improve management and reordering of inventory. omnicell® products range from high-security, closed-cabinet systems and software to open-shelf and combination systems in the nursing unit, cath lab, and operating room. more than 3,200 customers worldwide have utilized omnice
Organization | Omnicell Inc |
Employees | 3650 |
CEO | Mr. Randall A. Lipps |
Industry | Technology Services |